[A24-79] Dupilumab (COPD) – Benefit assessment according to §35a Social Code Book V
Last updated 06.03.2025
Project no.:
A24-79
Commission:
Commission awarded on 31.07.2024 by the Federal Joint Committee (GBA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Airways and respiratory system
Add-on maintenance treatment of adult patients with uncontrolled COPD characterized by raised blood eosinophils on a combination of an inhaled corticosteroid, a long-acting beta-2 agonist (LABA), and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA if an inhaled corticosteroid is not appropriate
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
The current version 1.1 of the Dossier assessment replaces version 1.0 published on 2024-11-04.
https://doi.org/10.60584/A24-79_en
Federal Joint Committee (G-BA)
2025-02-06 A G-BA decision was published.